Skip to main content
    A

    ARS Pharmaceuticals, Inc (SPRY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.59
    -0.30 (-7.71%)

    Market Cap: $391.06M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    ARS Pharmaceuticals, Inc (SPRY) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    ARS Pharmaceuticals reported revenue of $84.28M for the fiscal year ended Dec 31, 2025, down 5.5% from the year before. That year, net income was -$171.30M with a net margin of -203.3%, operating cash flow was -$170.87M and free cash flow was -$171.21M. The quarter ended Sep 30, 2026 had revenue of $37.71M and net income of -$35.59M.

    Revenue and Margins

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$84.28M-5.5%100.0%-212.9%-203.3%
    Dec 2024$89.15M+297063.3%98.9%-3.5%9.0%
    Dec 2023$30.00K-97.7%100.0%-225066.7%-181216.7%
    Dec 2022$1.32M-76.1%100.0%-2698.8%-2635.4%
    Dec 2021$5.51MN/A100.0%-353.3%-367.7%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019N/AN/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$84.28M$89.15M$30.00K$1.32M$5.51M$0N/AN/A
    Cost of revenue$0$977.00K$0$0$0$0$1.55M$1.42M
    Gross profit$84.28M$88.17M$30.00K$1.32M$5.51M$0-$1.55M-$1.42M
    Research and development$13.18M$19.58M$20.27M$18.38M$20.27M$24.58M$21.50M$14.80M
    Operating income-$179.45M-$3.08M-$67.52M-$35.52M-$19.45M-$32.92M-$24.07M-$18.32M
    Net income-$171.30M$8.00M-$54.37M-$34.68M-$20.24M-$32.95M-$23.97M-$17.58M
    EBITDA-$175.53M$1.11M-$61.14M-$34.22MN/A-$32.25M-$22.52M-$16.90M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$37.71M$33.66M$22.68M$28.09M$32.50M$15.72M$7.97M$86.58M$2.07M$500.00K$0-$30.00K
    Gross profit$27.61M$20.81M$16.39M$29.18M$24.31M$10.73M$6.88M$85.60M$2.07M$500.00K$0-$3.40M
    Operating income-$34.17M-$61.47M-$60.15M-$41.47M-$53.19M-$47.61M-$37.18M$47.20M-$21.75M-$15.34M-$13.19M-$10.23M
    Net income-$35.59M-$62.34M-$60.62M-$41.32M-$51.15M-$44.88M-$33.94M$49.93M-$19.13M-$12.52M-$10.29M-$7.17M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $96.96M exceeded cash and equivalents by $55.65M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$327.65M$351.15M$233.19M$281.44M$61.45M$394.80M$15.65M$27.55M
    Current assets$284.90M$334.30M$231.73M$277.70M$60.73M$390.66M$10.53M$20.78M
    Cash and equivalents$41.32M$50.82M$70.97M$210.52M$60.06M$386.57M$9.98M$20.16M
    Total liabilities$213.39M$94.36M$2.43M$8.55M$16.68M$11.93M$21.25M$9.35M
    Short-term debt$588.00K$42.00K$0$230.00K$3.48M$844.00K$12.30M$3.53M
    Long-term debt$96.37M$0N/AN/A$4.93M$7.46MN/AN/A
    Shareholder equity$114.26M$256.80M$230.76M$272.89M-$31.27M$382.88M-$5.60M$18.20M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$251.48M$249.50M$287.57M$327.65M$372.80M$313.47M$327.32M$351.15M$217.60M$221.97M$227.58M$233.19M
    Total liabilities$263.44M$236.98M$226.26M$213.39M$225.15M$121.15M$98.34M$94.36M$16.62M$6.72M$3.71M$2.43M
    Cash and equivalents$25.62M$8.16M$24.32M$41.32M$59.56M$51.54M$39.86M$50.82M$39.66M$36.63M$56.01M$70.97M
    Shareholder equity-$11.96M$12.51M$61.31M$114.26M$147.66M$192.32M$228.97M$256.80M$200.98M$215.24M$223.87M$230.76M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$170.87M$13.55M-$59.27M-$40.08M-$17.56M-$31.20M-$18.90M-$16.88M
    Capital expenditures$339.00K$563.00K$175.00K$199.00K$55.00K$917.00K$96.00K$449.00K
    Free cash flow-$171.21M$12.98M-$59.44M-$40.28M-$17.62M-$32.11M-$18.99M-$17.32M
    Investing cash flow$56.77M-$106.10M-$87.18M-$199.00K-$55.00K-$917.00K-$96.00K-$449.00K
    Financing cash flow$104.60M$72.40M$6.90M$190.73M$53.16M$408.51M$8.61M$19.40M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$33.71M-$60.93M-$44.95M-$43.48M-$47.05M-$39.59M-$40.74M$42.00M-$14.47M-$7.28M-$6.71M-$17.41M
    Capital expendituresN/AN/A$0$0$197.00K$51.00K$91.00K$302.00K$140.00K$38.00K$83.00K$91.00K
    Free cash flowN/AN/A-$44.95M-$43.48M-$47.24M-$39.64M-$40.83M$41.70M-$14.61M-$7.32M-$6.79M-$17.50M
    Last 12 quarters

    Frequently Asked Questions About SPRY

    What is ARS Pharmaceuticals' annual revenue?

    ARS Pharmaceuticals reported revenue of $84.28M for the fiscal year ended Dec 31, 2025.

    How fast is ARS Pharmaceuticals' revenue growing?

    Revenue was down 5.5% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 300.1%.

    Is ARS Pharmaceuticals profitable?

    No. ARS Pharmaceuticals reported net income of -$171.30M for the fiscal year ended Dec 31, 2025, with a net margin of -203.3%.

    How much free cash flow does SPRY generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$170.87M minus capital expenditures of $339.00K produced free cash flow of -$171.21M.

    How much debt does ARS Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $96.37M, short-term debt of $588.00K and cash and equivalents of $41.32M.